ArticleWorld journal of urology2026
Impact of a robotic-assisted transperineal biopsy platform on pathologic upgrading and downgrading at prostatectomy.
Article in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePathologic concordance between prostate biopsy and radical prostatectomy (RP) remains suboptimal, even in the era of multiparametric MRI-targeted and transperineal sampling. We aimed to assess whether high-precision lesion targeting using a novel robotic-assisted transperineal fusion biopsy (RA-TP-FBx) platform reduces rates of upgrading and downgrading between biopsy and prostatectomy specimens and thus improves concordance.
methodsWe reviewed all RA-TP-FBx cases recorded in the prospectively maintained database of a tertiary center between 2020 and 2024. Patients who subsequently underwent RP were included for analysis. Biopsies were performed using the iSR'obot Mona Lisa (Biobot) platform. In the presence of PI-RADS ≥ 3 lesions, both targeted and systematic biopsies were obtained. All biopsies, prostatectomies, and histopathological evaluations were conducted at a single institution. The total ISUP grade at biopsy was compared with final pathology following RP. Concordance, upgrading, and downgrading were reported as proportions, and agreement was quantified using Cohen’s kappa coefficient.
resultsA total of 448 men underwent RA-TP-FBx, of whom 118 (25.8%) subsequently underwent RP. Overall concordance between biopsy and final pathology was observed in 83.9% (99/118). ISUP upgrading occurred in 11.9% (14/118), while downgrading was observed in 4.2% (5/118). The corresponding Cohen’s kappa coefficient was 0.71, indicating good agreement.
conclusionsRA-TP-FBx demonstrated a high biopsy–prostatectomy concordance rate, ranking among the highest reported to date. These findings indicate that high concordance is achievable, challenge the notion that prostate biopsy is inherently limited in reflecting whole-mount pathology and suggest that robotic guidance may enhance lesion targeting and grading accuracy, supporting more reliable risk stratification and treatment planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.